MetLife, Inc. (MET) continued its upward trend with the stock climbing 0.63% or $0.33 to close the day at $52.91 on light trading volume of 4.98M shares, compared to its three month average trading volume of 6.4M. The New York New York 10166 based company has been outperforming the life insurance group over the past 52 weeks, with the stock gaining 55.53%, compared to the industry which has advanced 55.42% over the same period. With RSI of 45.34, the stock should still continue to rise and get closer to its one year target estimate of $59.86, making it a hold for now.
MetLife, Inc. provides life insurance, annuities, employee benefits, and asset management products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. It operates in six segments: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; Latin America; Asia; and Europe, the Middle East and Africa. The company provides variable, universal, term, and whole life products; individual disability income products; personal lines property and casualty insurance, including private passenger automobile, homeowners, and personal excess liability insurance; and variable and fixed annuities for asset accumulation and distribution needs, as well as mutual funds and other securities products. It also offers group insurance products, such as variable, universal, and term life products; dental, group short- and long-term disability, and accidental death and dismemberment coverages; and voluntary and worksite products consisting of personal lines property and casualty insurance, as well as LTC, prepaid legal plans, and critical illness products. In addition, the company provides annuity and investment products comprising guaranteed interest products and other stable value products, income annuities, and separate account contracts for the investment management of defined benefit and defined contribution plan assets; and structured settlements and products to fund postretirement benefits and company-, bank- or trust-owned life insurance, as well as health insurance, group medical, credit insurance, endowment, retirement, and savings products. It serves individuals and corporations, as well as other institutions and their employees. The company sells its products through sales forces, third-party organizations, independent agents, and property and casualty specialists, as well as through career agency, bancassurance, direct marketing, brokerage, and e-commerce channels. MetLife, Inc. was founded in 1863 and is based in New York, New York.
Boston Scientific Corporation (BSX) fell -0.55% during last trading as the stock lost $-0.14 to finish the day at $25.2 with about 4.95M shares changing hands, compared to its three month average trading volume of 8.33M. The $34.5B market cap company, which fluctuated between $25.2 and $25.43 during the day, currently situated 53.66% above its 52 week low of $16.62 and -0.98% away from its one year high of $25.45. The RSI of 76.47 indicates the stock is overbought at the current levels, sell for now.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Reynolds American Inc. (RAI) saw its value increase by 0.05% as the stock gained $0.03 to finish the day at a closing price of $60.57. The stock was lighter in trading and has fluctuated between $43.38-$60.91 per share for the past year. The shares, which traded within a range of $60.4 to $60.67 during the day, are up by 12.01% in the past three months and up by 23.02% over the past six months. It is currently trading 2.18% above its 20 day moving average and 6.38% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $57.01 a share over the next twelve months. The current relative strength index (RSI) reading is 77.18. The technical indicator do not lead us to believe the stock will see more gains any time soon.
Reynolds American Inc., through its subsidiaries, manufactures, and sells cigarettes and other tobacco products in the United States. It operates through RJR Tobacco, Santa Fe, and American Snuff segments. The RJR Tobacco segment offers cigarettes under the NEWPORT, CAMEL, PALL MALL, DORAL, MISTY, and CAPRI brands; and CAMEL Snus, a smoke-free tobacco product, as well as manages various licensed brands, including DUNHILL and STATE EXPRESS 555. The Santa Fe segment manufactures and markets cigarettes and other tobacco products under the NATURAL AMERICAN SPIRIT brand. The American Snuff segment provides smokeless tobacco products, such as moist snuff under GRIZZLY and KODIAK brand names. The company also manufactures and markets digital vapor cigarettes under the VUSE brand name; and markets nicotine replacement therapy products under the ZONNIC brand. It distributes its products primarily through direct wholesale deliveries from a local distribution center and public warehouses. Reynolds American Inc. was founded in 2004 and is headquartered in Winston-Salem, North Carolina.